Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(10%)

Phase Distribution

Ph not_applicable
1
10%
Ph phase_2
2
20%
Ph phase_3
2
20%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(4)
Terminated(1)
Other(5)

Detailed Status

unknown5
Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (40.0%)
Phase 32 (40.0%)
N/A1 (20.0%)

Trials by Status

completed440%
unknown550%
terminated110%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism

NCT01441557
unknown

Treatment Use of 3,4-Diaminopyridine

NCT01765140
unknown

Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia

NCT03062631
unknown

3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

NCT00872950
terminatedphase_3

DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome

NCT00701077
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT01441557Phase 2

Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism

Completed
NCT01765140

Treatment Use of 3,4-Diaminopyridine

Unknown
NCT03062631

Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia

Unknown
NCT00872950

3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

Unknown
NCT00701077Phase 3

DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome

Terminated
NCT02012933

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

Unknown
NCT00004832Not Applicable

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

Completed
NCT01378546

Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

Unknown
NCT00190268Phase 3

Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis

Completed
NCT00342381Phase 2

Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10